Edition:
United Kingdom

DBV Technologies SA (DBV.PA)

DBV.PA on Paris Stock Exchange

43.40EUR
11:58am BST
Change (% chg)

€2.42 (+5.91%)
Prev Close
€40.98
Open
€41.12
Day's High
€44.00
Day's Low
€41.12
Volume
114,881
Avg. Vol
78,468
52-wk High
€86.64
52-wk Low
€28.54

Latest Key Developments (Source: Significant Developments)

DBV Technologies Cash And Cash Equivalents Is At EUR 202.2 Million As Of June 30, 2018
Friday, 27 Jul 2018 

July 27 (Reuters) - Dbv Technologies Sa ::CASH AND CASH EQUIVALENTS AS OF JUNE 30, 2018, WERE EUR 202.2 MILLION, COMPARED TO EUR 137.9 MILLION AS OF DECEMBER 31, 2017.  Full Article

DBV Technologies: Closing Of Underwriters' Option To Purchase Additional Shares In Global Offering
Monday, 26 Mar 2018 

March 26 (Reuters) - DBV TECHNOLOGIES SA ::REG-DBV TECHNOLOGIES ANNOUNCES CLOSING OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES IN GLOBAL OFFERING.FOLLOWING OPTION CLOSING, GROSS PROCEEDS TO COMPANY FROM GLOBAL OFFERING ARE APPROXIMATELY $172.5 MILLION.  Full Article

DBV Technologies ‍Announces Intention To Issue And Sell Up To $150 Mln Of New Ordinary Shares​
Tuesday, 20 Mar 2018 

March 20 (Reuters) - Dbv Technologies Sa ::DBV TECHNOLOGIES ANNOUNCES THE LAUNCH OF A PROPOSED GLOBAL OFFERING OF ORDINARY SHARES, WHICH MAY BE IN THE FORM OF AMERICAN DEPOSITARY SHARES.DBV TECHNOLOGIES SA - ‍ANNOUNCED INTENTION TO ISSUE AND SELL UP TO $150.0 MILLION OF NEW ORDINARY SHARES​.DBV TECHNOLOGIES SA - ‍PLANS TO USE NET PROCEEDS FROM GLOBAL OFFERING TO FUND DEVELOPMENT AND COMMERCIALIZATION OF VIASKIN PEANUT, OTHERS ​.  Full Article

DBV Technologies says Viaskin Peanut study demonstrates good tolerance and safety of product
Monday, 20 Nov 2017 

Nov 20 (Reuters) - DBV TECHNOLOGIES SA ::SAYS STUDY DEMONSTRATES GOOD TOLERANCE AND SAFETY OF PRODUCT, COMPARABLE TO PREVIOUS STUDIES.FIST PERIOD OF STUDY COMPARED SAFETY OF TREATMENT WITH VIASKIN PEANUT 250 ΜG TO PLACEBO FOR 6 MTHS.RESULTS WILL SERVE AS A BASIS FOR PLANNED DISCUSSIONS WITH REGULATORY AUTHORITIES.SOME SERIOUS ADVERSE EVENTS WERE OBSERVED IN THE TRIAL.PATIENTS WHO COMPLETED FIRST PART OF STUDY WILL RECEIVE ACTIVE TREATMENT FOR 36 MTHS.  Full Article

DBV Technologies ‍announces positive data from Phase IIb trial and long-term study of Viaskin Peanut​
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - DBV TECHNOLOGIES SA ::‍ANNOUNCES PUBLICATION OF POSITIVE DATA FROM PHASE IIB TRIAL AND LONG-TERM STUDY OF VIASKIN PEANUT​.‍PRIMARY ENDPOINT OF PHASE IIB STUDY WAS MET AFTER 12 MONTHS OF TREATMENT​.‍LONG-TERM EXTENSION DATA SHOWED TREATMENT BENEFIT INCREASES OVER TIME​.‍ONGOING VIASKIN PEANUT PHASE III PROGRAM INCLUDES THREE GLOBAL STUDIES IN CHILDREN​.  Full Article

DBV Technologies reports at Sept. 30 cash position of 170.5 million euros
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - DBV TECHNOLOGIES SA ::CASH POSITION AT SEPT. 30, 2017 EUR 170.5 MILLION VERSUS EUR 256.5 MILLION AT DEC. 31, 2016 ‍​.  Full Article

DBV Technologies ‍cash position of 170.5 million euros as of September 30​
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - DBV TECHNOLOGIES SA ::‍CASH AND CASH EQUIVALENTS AS OF SEPTEMBER 30, 2017, WERE EUR 170.5 MILLION, COMPARED TO EUR 256.5 MILLION AS OF DECEMBER 31, 2016.​.  Full Article

DBV Technologies peanut allergy treatment fails to meet main goal in late-stage study
Friday, 20 Oct 2017 

Oct 20 (Reuters) - Dbv Technologies Sa :DBV Technologies announces topline results of phase III clinical trial in peanut-allergic patients four to 11 years of age‍​.DBV Technologies - topline results show statistically significant response with a favorable tolerability profile.DBV Technologies - primary endpoint did not reach 15% lower bound of CI that was proposed in study’s statistical analysis plan‍​.DBV Technologies - DBV will continue ongoing discussions with FDA, and plans to proceed with the BLA preparation process.  Full Article

DBV Technologies completes blinded period in REALISE study of Viaskin Peanut
Thursday, 12 Oct 2017 

Oct 12 (Reuters) - DBV TECHNOLOGIES SA ::REG-DBV TECHNOLOGIES ANNOUNCES COMPLETION OF BLINDED PERIOD IN REALISE STUDY OF VIASKIN PEANUT.‍97.5% OF PATIENTS CONTINUE TREATMENT IN OPEN-LABEL ARM OF REALISE STUDY​.‍PATIENTS WILL RECEIVE ACTIVE TREATMENT FOR A TOTAL OF 36 MONTHS​.‍COMPANY ANTICIPATES ANNOUNCING TOPLINE RESULTS FROM BLINDED PORTION OF REALISE TRIAL IN NOVEMBER 2017​.  Full Article

Photo

Scientists devise new, more accurate peanut allergy test

LONDON British scientists have developed a far more accurate blood test to diagnose peanut allergy, offering a better way to monitor a significant food hazard. | Video